210 related articles for article (PubMed ID: 36875652)
1. Disease-associated oligodendrocyte signatures are spatiotemporally dysregulated in spinocerebellar ataxia type 3.
Schuster KH; DiFranco DM; Putka AF; Mato JP; Jarrah SI; Stec NR; Sundararajan VO; McLoughlin HS
Front Neurosci; 2023; 17():1118429. PubMed ID: 36875652
[TBL] [Abstract][Full Text] [Related]
2. Impaired Oligodendrocyte Maturation Is an Early Feature in SCA3 Disease Pathogenesis.
Schuster KH; Zalon AJ; Zhang H; DiFranco DM; Stec NR; Haque Z; Blumenstein KG; Pierce AM; Guan Y; Paulson HL; McLoughlin HS
J Neurosci; 2022 Feb; 42(8):1604-1617. PubMed ID: 35042771
[TBL] [Abstract][Full Text] [Related]
3. ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice.
Schuster KH; Zalon AJ; DiFranco DM; Putka AF; Stec NR; Jarrah SI; Naeem A; Haque Z; Zhang H; Guan Y; McLoughlin HS
Mol Ther; 2024 May; 32(5):1359-1372. PubMed ID: 38429929
[TBL] [Abstract][Full Text] [Related]
4. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.
Ramani B; Panwar B; Moore LR; Wang B; Huang R; Guan Y; Paulson HL
Hum Mol Genet; 2017 Sep; 26(17):3362-3374. PubMed ID: 28854700
[TBL] [Abstract][Full Text] [Related]
5. Pathogenetic Mechanisms Underlying Spinocerebellar Ataxia Type 3 Are Altered in Primary Oligodendrocyte Culture.
Schuster KH; Putka AF; McLoughlin HS
Cells; 2022 Aug; 11(16):. PubMed ID: 36010688
[TBL] [Abstract][Full Text] [Related]
6. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M
Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414
[TBL] [Abstract][Full Text] [Related]
7. Regional and age-dependent changes in ubiquitination in cellular and mouse models of spinocerebellar ataxia type 3.
Luo H; Todi SV; Paulson HL; Costa MDC
Front Mol Neurosci; 2023; 16():1154203. PubMed ID: 37122622
[TBL] [Abstract][Full Text] [Related]
8. Urine levels of the polyglutamine ataxin-3 protein are elevated in patients with spinocerebellar ataxia type 3.
Koike Y; Jansen-West KR; Hanna Al-Shaikh R; Carlomagno Y; Song Y; Dunmore JA; LeDoux MS; Friedman JH; Pena AB; Uitti RJ; Zaremba J; van Gerpen JA; Pfeiffer RF; Veerappan V; Aiba I; Hashimoto R; Giles SS; Shah JS; Tipton PW; Huang JF; Wierenga KJ; Aasly J; Fryer JD; Petrucelli L; Wszolek ZK; Prudencio M
Parkinsonism Relat Disord; 2021 Aug; 89():151-154. PubMed ID: 34303201
[TBL] [Abstract][Full Text] [Related]
9. Plasma PolyQ-ATXN3 Levels Associate With Cerebellar Degeneration and Behavioral Abnormalities in a New AAV-Based SCA3 Mouse Model.
Jansen-West K; Todd TW; Daughrity LM; Yue M; Tong J; Carlomagno Y; Del Rosso G; Kurti A; Jones CY; Dunmore JA; Castanedes-Casey M; Dickson DW; Wszolek ZK; Fryer JD; Petrucelli L; Prudencio M
Front Cell Dev Biol; 2022; 10():863089. PubMed ID: 35386195
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of SCA3 and implications for other polyglutamine diseases.
McLoughlin HS; Moore LR; Paulson HL
Neurobiol Dis; 2020 Feb; 134():104635. PubMed ID: 31669734
[TBL] [Abstract][Full Text] [Related]
11. Spinocerebellar Ataxia Type 3 Pathophysiology-Implications for Translational Research and Clinical Studies.
Stahl F; Evert BO; Han X; Breuer P; Wüllner U
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612794
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models.
Moore LR; Rajpal G; Dillingham IT; Qutob M; Blumenstein KG; Gattis D; Hung G; Kordasiewicz HB; Paulson HL; McLoughlin HS
Mol Ther Nucleic Acids; 2017 Jun; 7():200-210. PubMed ID: 28624196
[TBL] [Abstract][Full Text] [Related]
13. Regional and age-dependent changes in ubiquitination in cellular and mouse models of Spinocerebellar ataxia type 3.
Luo H; Todi SV; Paulson HL; Costa MDC
bioRxiv; 2023 Feb; ():. PubMed ID: 36891289
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9 mediated gene correction ameliorates abnormal phenotypes in spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cells.
He L; Wang S; Peng L; Zhao H; Li S; Han X; Habimana JD; Chen Z; Wang C; Peng Y; Peng H; Xie Y; Lei L; Deng Q; Wan L; Wan N; Yuan H; Gong Y; Zou G; Li Z; Tang B; Jiang H
Transl Psychiatry; 2021 Sep; 11(1):479. PubMed ID: 34535635
[TBL] [Abstract][Full Text] [Related]
15. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein.
Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC
Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of PNKP by mutant ATXN3 triggers apoptosis by activating the DNA damage-response pathway in SCA3.
Gao R; Liu Y; Silva-Fernandes A; Fang X; Paulucci-Holthauzen A; Chatterjee A; Zhang HL; Matsuura T; Choudhary S; Ashizawa T; Koeppen AH; Maciel P; Hazra TK; Sarkar PS
PLoS Genet; 2015 Jan; 11(1):e1004834. PubMed ID: 25590633
[TBL] [Abstract][Full Text] [Related]
17. Frequency of SCA1, SCA2, SCA3/MJD, SCA6, SCA7, and DRPLA CAG trinucleotide repeat expansion in patients with hereditary spinocerebellar ataxia from Chinese kindreds.
Tang B; Liu C; Shen L; Dai H; Pan Q; Jing L; Ouyang S; Xia J
Arch Neurol; 2000 Apr; 57(4):540-4. PubMed ID: 10768629
[TBL] [Abstract][Full Text] [Related]
18. High Serum GFAP Levels in SCA3/MJD May Not Correlate with Disease Progression.
Shi Y; Wang C; Huang F; Chen Z; Sun Z; Wang J; Tang B; Ashizawa T; Klockgether T; Jiang H
Cerebellum; 2015 Dec; 14(6):677-81. PubMed ID: 25869927
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model.
Toonen LJA; Overzier M; Evers MM; Leon LG; van der Zeeuw SAJ; Mei H; Kielbasa SM; Goeman JJ; Hettne KM; Magnusson OT; Poirel M; Seyer A; 't Hoen PAC; van Roon-Mom WMC
Mol Neurodegener; 2018 Jun; 13(1):31. PubMed ID: 29929540
[TBL] [Abstract][Full Text] [Related]
20. Altered Levels of Proteins and Phosphoproteins, in the Absence of Early Causative Transcriptional Changes, Shape the Molecular Pathogenesis in the Brain of Young Presymptomatic Ki91 SCA3/MJD Mouse.
Wiatr K; Piasecki P; Marczak Ł; Wojciechowski P; Kurkowiak M; Płoski R; Rydzanicz M; Handschuh L; Jungverdorben J; Brüstle O; Figlerowicz M; Figiel M
Mol Neurobiol; 2019 Dec; 56(12):8168-8202. PubMed ID: 31201651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
